Stein Bergan
Position: Professor II, PhD
Phone: 23071082
Email:
 

Author network for Stein Bergan by COREMINE medical


Publications 2017

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2017)
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Br J Clin Pharmacol (in press)
PubMed 28146606

Publications 2016

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M (2016)
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
Ther Drug Monit, 38 Suppl 1, S1-20
PubMed 26977997

Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H (2016)
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
PubMed 26885529

Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V (2016)
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Ther Drug Monit, 38 Suppl 1, S57-69
PubMed 26469711

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2016)
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance
Br J Clin Pharmacol (in press)
PubMed 28008657

Størset E, von Düring ME, Godang K, Bergan S, Midtvedt K, Åsberg A (2016)
Prediction of Fat-Free Mass in Kidney Transplant Recipients
Ther Drug Monit, 38 (4), 439-46
PubMed 27019101

Størset E, Åsberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K (2016)
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology (Carlton), 21 (10), 821-7
PubMed 26854648

Publications 2015

Bergan S, Bremer S, Vethe NT (2015)
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
PubMed 26453533

Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S (2015)
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
PubMed 25565670

Cehajic I, Bergan S, Bjordal K (2015)
Pharmacist assessment of drug-related problems on an oncology ward
Eur. J. Hosp. Pharm.-Sci. Pract., 22 (4), 194-197

de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA (2015)
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
Ther Drug Monit, 37 (5), 560-7
PubMed 25551406

Karlsen Bjånes T, Mjåset Hjertø E, Lønne L, Aronsen L, Andsnes Berg J, Bergan S, Otto Berg-Hansen G, Bernard JP, Larsen Burns M, Toralf Fosen J, Frost J, Hilberg T, Krabseth HM, Kvan E, Narum S, Austgulen Westin A (2015)
Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services
Clin Ther, 38 (1), 222-6
PubMed 26546404

Kloster-Jensen K, Vethe NT, Bremer S, Abadpour S, Korsgren O, Foss A, Bergan S, Scholz H (2015)
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
PubMed 26046470

Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015)
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
PubMed 25148382

Salvador CL, Tøndel C, Mørkrid L, Bjerre A, Brun A, Bolann B, Brackman D, Bergan S (2015)
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots
Scand J Clin Lab Invest, 75 (8), 710-6
PubMed 26426851

Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K (2015)
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study
Transplantation, 99 (10), 2158-66
PubMed 25886918

Publications 2014

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
PubMed 25178233

Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K, Nordic Society of Paediatric Haematology, Oncology (2014)
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer
Pediatr Blood Cancer, 61 (5), 797-802
PubMed 24395436

Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Åsberg A, Christensen H (2014)
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Eur J Clin Pharmacol, 70 (6), 685-93
PubMed 24658827

Størset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, Åsberg A, Midtvedt K, Staatz CE (2014)
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
Br J Clin Pharmacol, 78 (3), 509-23
PubMed 25279405

Sæves I, Line PD, Bremer S, Vethe NT, Tveit RG, Meltevik TJ, Bergan S (2014)
Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
Ther Drug Monit, 36 (1), 46-53
PubMed 24081206

Vethe NT, Ali AM, Reine PA, Andersen AM, Bremer S, Line PD, Rootwelt H, Bergan S (2014)
Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid
Ther Drug Monit, 36 (1), 108-18
PubMed 24061448

Publications 2013

Lærum H, Bremer S, Bergan S, Grünfeld T (2013)
A taste of individualized medicine: physicians' reactions to automated genetic interpretations
J Am Med Inform Assoc, 21 (e1), e143-6
PubMed 24001515

Reine PA, Vethe NT, Kongsgaard UE, Andersen AM, Line PD, Ali AM, Bergan S (2013)
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand J Clin Lab Invest, 73 (2), 117-24
PubMed 23281843

Størset E, Holford N, Midtvedt K, Bremer S, Bergan S, Åsberg A (2013)
Importance of hematocrit for a tacrolimus target concentration strategy
Eur J Clin Pharmacol, 70 (1), 65-77
PubMed 24071959

Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN (2013)
Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
Transpl Int, 26 (12), 1198-207
PubMed 24118301

Publications 2012

Gjersvik P, Helsing P, Holdaas H, Bergan S (2012)
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]
Tidsskr Nor Laegeforen, 132 (18), 2064-8
PubMed 23038197

Sæves I, Line PD, Bergan S (2012)
The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation
Ther Drug Monit, 34 (4), 452-9
PubMed 22777155

Publications 2011

Midtvedt K, Jenssen T, Hartmann A, Vethe NT, Bergan S, Havnes K, Åsberg A (2011)
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol Dial Transplant, 26 (11), 3767-72
PubMed 21471328

Sæves I, Vethe NT, Bergan S (2011)
Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects
Ther Drug Monit, 33 (4), 402-10
PubMed 21743383

Vethe NT, Midtvedt K, Asberg A, Amundsen R, Bergan S (2011)
[Drug interactions and immunosuppression in organ transplant recipients]
Tidsskr Nor Laegeforen, 131 (20), 2000-3
PubMed 22016125

Publications 2010

Vethe NT, Gjerdalen LC, Bergan S (2010)
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
Scand J Clin Lab Invest, 70 (8), 583-91
PubMed 21039189

Publications 2009

Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, Midtvedt K (2009)
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
Transplantation, 87 (8), 1221-4
PubMed 19384170

Bremer S, Vethe NT, Rootwelt H, Jørgensen PF, Stenstrøm J, Holdaas H, Midtvedt K, Bergan S (2009)
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
PubMed 19635156

Iversen M, Nilsson F, Sipponen J, Eiskjaer H, Mared L, Bergan S, Nyström U, Fagertun HE, Solbu D, Simonsen S (2009)
Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study
J Heart Lung Transplant, 28 (9), 919-26
PubMed 19716045

Oiestad EL, Johansen U, Stokke Opdal M, Bergan S, Christophersen AS (2009)
Determination of digoxin and digitoxin in whole blood
J Anal Toxicol, 33 (7), 372-8
PubMed 19796507

Publications 2008

Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S (2008)
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
PubMed 18192912

Bremer S, Vethe NT, Rootwelt H, Bergan S (2008)
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int Immunopharmacol, 9 (2), 173-80
PubMed 19010451

Falck P, Asberg A, Byberg KT, Bremer S, Bergan S, Reubsaet JL, Midtvedt K (2008)
Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients
Transplantation, 86 (10), 1379-83
PubMed 19034006

Ruud E, Holmstrøm H, Bergan S, Wesenberg F (2008)
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
Pediatr Blood Cancer, 50 (3), 710-3
PubMed 17226852

Vethe NT, Bremer S, Bergan S (2008)
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand J Clin Lab Invest, 68 (4), 277-85
PubMed 18609073

Vethe NT, Bremer S, Rootwelt H, Bergan S (2008)
Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals
Ther Drug Monit, 30 (6), 647-55
PubMed 18806697

Publications 2007

Bremer S, Rootwelt H, Bergan S (2007)
Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells
Clin Chem, 53 (6), 1023-9
PubMed 17463174

Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, Holdaas H (2007)
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
PubMed 17956893

Publications 2006

Bergan S, Rootwelt H (2006)
[Customized drugs?]
Tidsskr Nor Laegeforen, 126 (18), 2364
PubMed 16998544

Mandla R, Midtvedt K, Line PD, Hartmann A, Bergan S (2006)
Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients
Transpl Int, 19 (1), 44-53
PubMed 16359376

Oyen O, Strøm EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P, Brekke IB (2006)
Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome
Am J Transplant, 6 (2), 412-8
PubMed 16426329

Vethe NT, Bergan S (2006)
Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy
Ther Drug Monit, 28 (5), 608-13
PubMed 17038874

Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S (2006)
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Scand J Clin Lab Invest, 66 (1), 31-44
PubMed 16464785

Publications 2003

Bergan S (2003)
TDM: report concentration, Css, rather than area under the curve, AUC
Ther Drug Monit, 25 (6), 743
PubMed 14639063

Mandla R, Line PD, Midtvedt K, Bergan S (2003)
Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients
Ther Drug Monit, 25 (3), 407-14
PubMed 12766573

Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T (2003)
C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Transplantation, 76 (8), 1236-8
PubMed 14578761

Publications 2002

Chikuni O, Nhachi CF, Polder A, Bergan S, Nafstud I, Skaare JU (2002)
Effects of DDT on paracetamol half-life in highly exposed mothers in Zimbabwe
Toxicol Lett, 134 (1-3), 147-53
PubMed 12191873

Chikuni O, Nhachi CFB, Polder A, Bergan S, Nafstud I, Skaare JU (2002)
Effects of DDT on paracetamol half-life in highly exposed mothers in Zimbabwe
Toxicol. Lett., 134 (1-3), PII S0378-4274(02)00184-4-153

Johansen PW, Bergan S, Rootwelt H, Kvittingen EA, Rugstad HE (2002)
[Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping]
Tidsskr Nor Laegeforen, 122 (29), 2781-3
PubMed 12523145

Molden E, Johansen PW, Bøe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, Lehne G (2002)
Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
Clin Pharmacol Ther, 72 (3), 333-42
PubMed 12235455

Publications 2001

Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H (2001)
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am J Transplant, 1 (4), 382-6
PubMed 12099384

Publications 2000

Bergan S, Norge O (2000)
[Better therapeutic potential for azathioprine and mercaptopurine]
Lakartidningen, 97 (16), 1999-2000
PubMed 10826362

Publications 1999

Bergan S, Albrechtsen D, Bentdal O (1999)
[Immunosuppressive agents in organ transplantation]
Tidsskr Nor Laegeforen, 119 (24), 3615-20
PubMed 10563181

Publications 1998

Bergan S, Rugstad HE, Bentdal O, Sødal G, Hartmann A, Leivestad T, Stokke O (1998)
Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
Transplantation, 66 (3), 334-9
PubMed 9721802

Sagedal S, Asberg A, Hartmann A, Bergan S, Berg KJ (1998)
Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients
Clin Transplant, 12 (6), 553-6
PubMed 9850449

Publications 1997

Bergan S (1997)
Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements
BioDrugs, 8 (6), 446-56
PubMed 18031107

Bergan S, Bentdal O, Sødal G, Brun A, Rugstad HE, Stokke O (1997)
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts
Ther Drug Monit, 19 (5), 502-9
PubMed 9357091

Bergan S, Rugstad HE, Klemetsdal B, Giverhaug T, Bentdal O, Sødal G, Hartmann A, Aarbakke J, Stokke O (1997)
Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
Ther Drug Monit, 19 (3), 318-26
PubMed 9200774

Giverhaug T, Bergan S, Loennechen T, Rugstad HE, Aarbakke J (1997)
Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: comparison of two methods
Ther Drug Monit, 19 (6), 663-8
PubMed 9421108

Publications 1996

Bergan S, Albrechtsen D, Fauchald P (1996)
[Mycophenolate mofetil--a new immunosuppressive agent]
Tidsskr Nor Laegeforen, 116 (20), 2439-41
PubMed 8928103

Publications 1995

Bergan S, Rugstad HE, Bentdal O, Sødal G, Hartmann A, Klemetsdal B, Aarbakke J, Stokke O (1995)
Optimization of azathioprine therapy by measuring 6-thioguanine nucleotides and methylated mercaptopurine in renal allograft recipients
Transplant Proc, 27 (6), 3426
PubMed 8540033

Publications 1994

Bergan S, Rugstad HE, Bentdal O, Endresen L, Stokke O (1994)
Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment
Ther Drug Monit, 16 (1), 13-20
PubMed 8160249

Bergan S, Rugstad HE, Bentdal O, Stokke O (1994)
Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes
Transplantation, 58 (7), 803-8
PubMed 7940715

Publications 1993

Bergan S, Rugstad HE, Stokke O, Bentdal O, Frøysaker T, Bergan A (1993)
Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a comparison between fluorescence polarization immunoassay and two different RIA methods
Scand J Clin Lab Invest, 53 (5), 471-7
PubMed 8210969

Publications 1991

Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg KJ (1991)
Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients
Ther Drug Monit, 13 (6), 490-5
PubMed 1837629

Publications 1980

Bergan S, Laake K, Bjartveit K (1980)
[Side effects of antitubercular drugs leading to discontinuation of drug therapy]
Tidsskr Nor Laegeforen, 100 (5), 279-82
PubMed 7385151